BLEThe new features include a gaming activation area and an expanded brands and lifestyle theater program.

Online registration for Brand Licensing Europe (BLE), the largest licensing event in Europe, kicked off June 19 at The 19th annual event of BLE will be held Oct. 10-12 in Olympia London, United Kingdom.

Organized by UBM and sponsored by the International Licensing Industry Merchandisers’ Association (LIMA), at this year’s show, BLE will host several new visitor activations and exhibitors, including the new Gaming Activation Area, which will serve as an interactive space for demonstrations, competitions and highlight the potential of gaming at retail, from concept to store.

BLE will also feature an expanded Brands & Lifestyle Theatre Program to include more sessions during daily, as well as interactive performances and demonstrations each morning. There will also be a newly revamped Product Showcase.

“We are so excited to be rolling out these new initiatives for visitors to BLE in October,” BLE Brand Director Anna Knight said in a release. “Gaming is a huge untapped market – one we know our visitors will really benefit from discovering. And this year’s educational program is our most comprehensive yet – unmissable for both buyers and manufacturers whether new to, or already familiar with, the power of licensing in business.”


  • • BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose
    COVID-19 Phase 2 topline report to be submitted for consideration of emergency approval of leronlimab for patients with mild-to-moderate symptoms to U.K. and other countries following submission to the U.S. FDA next week

  • SHANGHAI, China, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the first patient has been dosed in a Phase 1b/2 study evaluating FGF401 in combination with PD-1 inhibitor, pembrolizumab, in patients with advanced solid tumors, such as hepatocellular carcinoma (HCC).

  • 中国上海, Aug. 07, 2020 (GLOBE NEWSWIRE) -- 云顶新耀(Everest Medicines),一家专注于创新药开发及商业化的生物制药公司,致力于满足大中华区及其它亚洲市场未被满足的医疗需求,今日宣布在FGF401联合PD-1抑制剂Pembrolizumab用于治疗晚期实体瘤(例如肝细胞癌)的1b/2期临床研究中完成首例受试者给药。

  • HOUSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Houston Wire & Cable Company (NASDAQ: HWCC) (the “Company”) announced operating results for the second quarter ended June 30, 2020 and progress on its cost and debt reduction programs.

  • CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. All of the shares are being offered by Checkmate. Checkmate’s common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol “CMPI” on August 7, 2020. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Checkmate, are expected to be approximately $75,000,000. The offering is expected to close on August 11, 2020, subject to the satisfaction of customary closing conditions. Checkmate has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Contact Us

Retail Merchandiser Magazine

Cringleford Business Centre,
Intwood Road Cringleford,
Norwich, UK, NR6 4AU

  +44 (0) 1603 274 130

Click here for a full list of contacts.

Back To Top